CLINICAL TRIALS PROFILE FOR CHEMET

All Clinical Trials for CHEMET

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03630991 ↗	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Recruiting	National Cancer Institute (NCI)	Phase 1	2018-10-11	This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.
NCT03630991 ↗	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy	Recruiting	M.D. Anderson Cancer Center	Phase 1	2018-10-11	This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.

Clinical Trial Conditions for CHEMET

Condition Name

Condition Name for CHEMET
Intervention	Trials
Secondary Myelodysplastic Syndrome	1
Myelodysplastic/Myeloproliferative Neoplasm	1
Very High Risk Myelodysplastic Syndrome	1
Myeloproliferative Neoplasm	1

Condition MeSH

Condition MeSH for CHEMET
Intervention	Trials
Leukemia, Myeloid	1
Myeloproliferative Disorders	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	1
Myelodysplastic-Myeloproliferative Diseases	1

Clinical Trial Locations for CHEMET

Trials by Country

Trials by Country for CHEMET
Location	Trials
United States	1

Trials by US State

Trials by US State for CHEMET
Location	Trials
Texas	1

Clinical Trial Progress for CHEMET

Clinical Trial Phase

Clinical Trial Phase for CHEMET
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CHEMET
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for CHEMET

Sponsor Name

Sponsor Name for CHEMET
Sponsor	Trials
National Cancer Institute (NCI)	1
M.D. Anderson Cancer Center	1

Sponsor Type

Sponsor Type for CHEMET
Sponsor	Trials
NIH	1
Other	1

Last updated: May 10, 2026

CHEMET: What do current clinical and market signals indicate for next-stage value?

What is CHEMET’s clinical development status?

Insufficient information is available to produce a complete, accurate, and properly sourced clinical-trials update for “CHEMET” (including indication, sponsor, mechanism, trial phases, enrollment status, endpoints, and readouts).

What is CHEMET’s market position and pricing power?

Insufficient information is available to produce a complete, accurate, and properly sourced market analysis for “CHEMET” (including approved/late-stage status, indication-level incidence and addressable population, competitor landscape, pricing benchmarks, and reimbursement dynamics).

What market projection is supportable for CHEMET?

Insufficient information is available to produce a complete, accurate, and properly sourced revenue or adoption projection for “CHEMET” (including timeline to approval, launch assumptions, penetration curves, uptake drivers, geographic scope, and patent/competition constraints).

---

Key Takeaways

• A complete clinical-trials update for CHEMET cannot be produced from the information available in this request.
• A complete market analysis and projection for CHEMET cannot be produced from the information available in this request.
• No indication, sponsor, mechanism, trial identifiers, endpoints, or comparable market benchmarks are provided, so no defensible numbers can be stated.

---

FAQs

1. What is CHEMET’s therapeutic target and mechanism of action?
   Not provided in the request, so it cannot be stated accurately.

2. Which indications and trial phases is CHEMET in?
   Not provided in the request, so it cannot be listed accurately.

3. What is CHEMET’s competitive landscape versus standard of care?
   Not provided in the request, so it cannot be analyzed accurately.

4. What is the expected launch timeline and revenue ramp for CHEMET?
   Not provided in the request, so it cannot be projected accurately.

5. What patent life and exclusivity risk shape CHEMET’s long-term upside?
   Not provided in the request, so it cannot be assessed accurately.

---

References

[1]